Patents by Inventor Aránzazu Garcia-Molina

Aránzazu Garcia-Molina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
    Patent number: 10584129
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: March 10, 2020
    Assignee: Janssen Pharmaceuticals NV
    Inventors: Sergio-Alvar Alonso-de Diego, José Maria Cid-Núñez, Óscar Delgado-González, Annelies Marie Antonius Decorte, Michiel Luc Maria Van Gool, Gregor James MacDonald, Antonius Adrianus Hendrikus Petrus Megens, Andrés Avelino Trabanco-Suárez, Aránzazu García-Molina, José Ignacio Andrés-Gil
  • SUBSTITUTED 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
    Publication number: 20190055257
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Application
    Filed: September 6, 2018
    Publication date: February 21, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Sergio-Alvar Alonso-de Diego, José Maria Cid-Núñez, Óscar Delgado-González, Annelies Marie Antonius Decorte, Michiel Luc Maria Van Gool, Gregor James MacDonald, Antonius Adrianus Hendrikus Petrus Megens, Andrés Avelino Trabanco-Suárez, Aránzazu García-Molina, José Ignacio Andrés-Gil
  • Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
    Patent number: 10106542
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of formula (I) as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”) useful for the treatment of central nervous system disorders in which the mGluR2 subtype of metabotropic receptors is involved (e.g. mood disorder, schizophrenia, etc.). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for treatment of central nervous system disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: October 23, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Sergio-Alvar Alonso-de Diego, José Maria Cid-Núñez, Óscar Delgado-González, Annelies Marie Antonius Decorte, Michiel Luc Maria Van Gool, Gregor James MacDonald, Antonius Adrianus Hendrikus Petrus Megens, Andrés Avelino Trabanco-Suárez, Aránzazu Garcia-Molina, José Ignacio Andrés-Gil